麻豆视频

Global Poultry Vaccines Market Trends and Insights

Increasing Incidences of Poultry & Zoonotic Diseases

In 2024-2025, H5N1 outbreaks led to record losses in 47 countries, prompting the United States to cull over 80 million birds and Mexico, along with parts of Europe, to initiate emergency vaccination drives.^{[1]U.S. Food and Drug Administration, 鈥淐enter for Veterinary Medicine: Antimicrobial Resistance in Veterinary Settings,鈥� FDA, www.fda.gov} Endemic Newcastle disease is causing 30%-50% mortality in backyard flocks in Indonesia, Nigeria, and Bangladesh, driving up the demand for thermostable drinking-water vaccines that circumvent cold-chain issues. Following human H5N1 cases in Cambodia and Vietnam, the World Health Organization emphasized public health measures, advocating for ring vaccinations of flocks within a 10 km radius of confirmed cases. As Marek鈥檚 disease evolves with increased virulence, producers are increasingly turning to bivalent HVT-based products. Additionally, coccidiosis continues to result in approximately USD 3 billion annually in performance losses, solidifying the role of live oocyst vaccines as a primary control method in antibiotic-free programs.

Regulatory Push to Replace Antibiotics with Vaccination

Since January 2022, the European Union has enforced a full ban on prophylactic antibiotics. This move has led to an increase in vaccine courses for clostridial and necrotic enteritis, with projections extending through 2025. In the United States, FDA Guidance 263 has not only curtailed the use of feed-grade antimicrobials but has also catalyzed a broader adoption of multivalent enteric vaccines. Meanwhile, Brazil's policy to cut colistin has driven national integrators to invest in autogenous programs targeting Salmonella and E. coli. In China, the ongoing ban on colistin has led to a 40% surge in domestic orders for inactivated doses of avian-pathogenic E. coli by 2025. This uptick is further bolstered by producers ramping up their capacity. Additionally, adherence to Codex residue limits has become a crucial requirement for exporters. This has pushed countries like Thailand, Argentina, and South Africa to intensify their focus on preventive immunization.

Rapid Expansion of Vertically Integrated Broiler Operations in ASEAN

In 2025, Thailand increased its broiler output by 12%, driven by the deployment of new hatcheries equipped with automated in-ovo units. These units administer vaccines for Marek鈥檚, infectious bursal disease, and Newcastle disease in a single pass. Meanwhile, Indonesia attracted USD 800 million in foreign direct investment (FDI) for 2024-2025. Japanese and Korean investors have mandated hatchery immunization specifically for export lines. In Vietnam, authorities approved the establishment of eight mega-complexes in 2025. Each complex is required to have inactivated avian influenza coverage for its parent stock. The Philippines is supporting smallholder upgrade loans that include mandatory vaccinations against Newcastle disease and infectious bursal disease. Additionally, Malaysia's halal regulations have expedited the adoption of plant-based media for vaccine production.

Improvements in Vectored & Combination Vaccinations

Recombinant HVT-based multivalent platforms provide durable immunity while bypassing maternal antibody interference, a property that has prompted several producers to redesign hatchery workflow around single-shot schedules. The unspoken benefit is inventory simplification; integrators report double-digit reductions in on-farm SKU counts, indirectly improving biosecurity by reducing handling errors. Peer-reviewed trials confirm that temperature-sensitive recombinant M41-R vaccines maintain tracheal ciliary activity post challenge.^{[2] United States Department of Agriculture, 鈥淗ighly Pathogenic Avian Influenza 2025 Response Plan,鈥� USDA, www.usda.gov} Companies are leveraging various virus vectors, such as fowl poxvirus, fowl adenovirus, Marek's disease virus, and Newcastle disease virus, for vaccine development, each withdisease challenges and reduced labor by 25% by consolidating three live-virus rounds into a single round unique benefits for targeted applications. This technological evolution is bolstering the competitive edge of firms with robust R&D in recombinant technologies, while it risks unsettling the market standing of those adhering strictly to traditional vaccine methods. Boehringer Ingelheim's Vaxxitek HVT+IBD+ND demonstrated 95% field efficacy against virulent Newcastle challenges and reduced labor by 25% by consolidating three live-virus rounds into one.

Counterfeit Products Eroding Producer Confidence

In 2024, the National Agency for Food and Drug Administration and Control (NAFDAC) aggressively targeted and destroyed unauthorized veterinary products, including counterfeit anthrax vaccines made of just water or sugar. These products, often found in "price-driven grey markets," were seized in states such as Kaduna, Nasarawa, and Oyo. NAFDAC emphasized the unregistered, frequently smuggled nature of these products, noting the challenges posed by porous borders. In 2024, they also confiscated significant quantities of "substandard and falsified" medicines. Meanwhile, the Kenya Veterinary Medicines Directorate (VMD) enforces stringent regulations on veterinary vaccines, such as Avian Influenza and East Coast Fever (ECF). They mandate a registration process for importers to ensure safety standards are upheld. The 15% failure rate in 2025 aligns with ongoing efforts to balance regulatory oversight between imported and locally produced vaccines, including those from the Kenya Veterinary Vaccines Production Institute (KEVEVAPI). This registry initiative is a key component of their strategic plan spanning from 2023 to 2027.

Cold-Chain Expense & Vaccine Hesitancy Among African Smallholders

In Sub-Saharan Africa, where electricity costs exceed OECD norms, maintaining doses between 2掳C and 8掳C adds an expense of USD 0.15-0.25 per shot. Despite receiving a 50% subsidy, surveys conducted in Uganda, Tanzania, and Mozambique revealed that only 22% of flocks were vaccinated against Newcastle disease. Farmers, having previously encountered issues with ineffective or expired vaccines, now prioritize spending their limited funds on feed or housing. While solar-powered refrigerators offer a potential solution, their high cost is a barrier. On the other hand, products derived from the thermostable I-2 strain can withstand ambient heat for up to seven days. However, they are still pending clearance due to the need for local stability dossiers.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Disease Type: Infectious Bronchitis Leads, Avian Influenza Surges

In 2025, vaccines for infectious bronchitis captured 22.85% of the poultry vaccine market, underscoring their importance in broiler, layer, and breeder operations. These vaccines address respiratory issues and shell-quality concerns that can impact profit margins. Meanwhile, avian influenza vaccines are projected to grow at a 9.00% compound annual growth rate (CAGR) through 2031. This surge is driven by culling costs and export bans, prompting governments in Mexico, Egypt, and Vietnam to enforce flock coverage mandates. 

Newcastle disease solutions remain essential in emerging markets. Thermostable I-2 formulations facilitate mass delivery through drinking water. For Marek鈥檚 disease, day-old or in-ovo herpesvirus of turkey (HVT)-SB1 blends are employed to counteract increasing virulence. Coccidiosis vaccines are gaining traction in drug-free programs that have eliminated ionophore feed additives.

By Technology: Live Attenuated Dominates, Recombinant Platforms Accelerate

In 2025, live attenuated products held a 38.40% share of the poultry vaccine market, valued for their ability to induce strong cellular immunity and their cost-effective spray-cabinet dosing method. Recombinant vectors, particularly HVT carriers that avoid maternal-antibody interference, are on a growth trajectory with a 9.25% CAGR. 

Despite their higher labor and dosage costs, inactivated vaccines play a crucial role for breeder and layer boosters, ensuring maternal antibodies are passed to chicks. Meanwhile, DNA and subunit vaccines are advancing through late-stage trials, valued for their rapid two-month antigen-update cycles that keep pace with swiftly mutating strains like H5 or GI-23.

By Application: Breeder Flocks Command Share, Layers Drive Growth

In 2025, breeder programs accounted for 44.20% of the revenue, utilizing maternal-antibody transfer to protect chicks in their crucial first three weeks. Layer flocks are anticipated to experience an 8.99% CAGR through 2031. This growth is attributed to cage-free systems extending their productive lifespan beyond 100 weeks, necessitating additional boosters. 

Broiler programs are increasingly reliant on automated in-ovo injections, capable of processing up to 80,000 eggs hourly. This efficiency not only reduces labor but also enhances cost competitiveness within the 35-day cycle.

By Dosage Form: Liquid Formulations Lead, Powder Gains Traction

In 2025, liquid vaccines accounted for 55.46% of the market. Their low viscosity makes them ideal for in-ovo needles and subcutaneous applications. Powder and dust formats are projected to grow at a 10.78% CAGR. Notably, lyophilized doses can remain effective for 48 hours at ambient temperatures, a significant advantage in areas with unreliable power supply. 

On-farm reconstitution of freeze-dried bricks simplifies hatchery spray routines. Additionally, while backpack aerosol powders are designed for backyard birds, there's variability in field coverage.

By Route of Administration: Injectable Dominates, Intranasal Surges

Injectables commanded a 56.85% market share in 2025, playing a crucial role for breeders and layers that require precise dosing. Intranasal sprays administered at day-old are witnessing a 10.95% CAGR. These sprays not only prevent puncture injuries but also reduce labor by 40% in hatcheries. 

Automated in-ovo systems are adept at inserting antigens on embryonic day 18, seamlessly integrating transfer, candling, and dosing processes. While drinking-water and spray-house methods effectively cover broilers, they come with the risk of uneven titer gaps due to inconsistent drinking or aerosol dispersion.

By End User: Poultry Farms Dominate, Veterinary Clinics Expand

Poultry farms, encompassing integrators, contract growers, and independents, accounted for 67.60% of the 2025 market. Meanwhile, veterinary clinics and hospitals are experiencing a robust growth rate of 10.22% CAGR. This surge is largely driven by smallholders in Africa and South Asia, who are increasingly seeking comprehensive advisory visits. These visits often bundle treatments for Newcastle, infectious bursal disease, and fowl pox. While research institutes may contribute modestly to revenue, their influence is significant, shaping regulatory approvals through efficacy trials and post-market surveillance.

By Distribution Channel: Hospital Pharmacies Lead, Online Platforms Surge

In 2025, hospital pharmacies accounted for 44.90% of the market turnover. Their value lies in batch tracking and oversight by pharmacists. Online platforms are witnessing a meteoric rise, boasting an 11.90% CAGR. This growth is fueled by integrators who consolidate orders, upload Internet of Things (IoT) temperature logs, and effectively reduce stock-outs by as much as 30%. While farm-supply stores remain relevant, especially in areas with limited internet access, they are gradually losing ground. E-commerce platforms are offering broader selections and transparent pricing, making them increasingly attractive to consumers.

Geography Analysis

North America retains a 33.50% market share in 2025. USDA indemnity payouts totaling USD 1.1 billion highlight the fiscal magnitude of HPAI. Insurers have begun to model policy premiums on whether a farm participates in USDA-approved vaccination programs, effectively turning vaccines into quasi-financial instruments that influence coverage costs.

Asia is the fastest-growing region, with a 9.48% CAGR outlook for 2026-2031. China鈥檚 historic 73% avian influenza vaccination coverage has prompted local labs to develop accelerated systems for monitoring viral evolution. Those surveillance assets double as competitive intelligence, allowing regional manufacturers to iterate on vaccines ahead of global peers.

Europe, Latin America, and the Middle East each display distinct triggers for vaccine uptake, from welfare regulations to export-market access requirements. Brazil鈥檚 export-oriented producers increasingly view vaccination status as a tool to mitigate tariffs. In contrast, GCC buyers fold vaccine clauses directly into long-term feed import contracts to ensure continuity of local protein supplies.

Regulatory Landscape

Global regulation of poultry vaccines is anchored in veterinary-biologics and veterinary-medicinal frameworks that govern product quality and use claims, and it increasingly intersects with trade rules for disease-controlled poultry. In the United States, veterinary biologics oversight under the Virus-Serum-Toxin Act is administered by the USDA (including the Center for Veterinary Biologics). In the European Union, veterinary medicinal products are regulated under Regulation (EU) 2019/6, with EMA guidance shaping dossier expectations for complex products such as multi-strain inactivated vaccines used in avian influenza programs.

At the international level, WOAH standards in the Terrestrial Animal Health Code and the Terrestrial Manual underpin vaccination and surveillance requirements referenced in SPS-aligned trade discussions. Recent standard-setting activity is also adding clarity for developers and regulators managing rapidly changing avian-disease risk. In February 2026, WOAH reported that an ad hoc group met to develop a harmonized Target Product Profile (TPP) template for veterinary vaccines, aligning expectations among regulators, researchers, and end-users for attributes beyond minimum safety and quality. In May 2025, WOAH adopted amendments to the Terrestrial Manual, including new chapters on transport of biological materials and standards for high-throughput sequencing, which reinforce the compliance stack supporting vaccine strain updates, batch movement, and monitoring of field-virus evolution.

Market Opportunities and Future Outlook

Programmatic shifts toward vaccination-based control and tighter regulatory pathways are creating whitespace for differentiated poultry vaccine portfolios, particularly in avian influenza (AI) and hatchery-delivered multivalent regimens. Governments and intergovernmental bodies are codifying rules that connect vaccination to surveillance and trade continuity, which is supporting demand for vaccines paired with monitoring and documentation capabilities. A visible example is India, where the Department of Animal Husbandry and Dairying established a structured regulatory pathway for the import and use of HPAI vaccines in June 2026, creating a defined entry route for manufacturers that can meet local data and field-strain requirements.

Product and capacity milestones in 2025-2026 also point to near-term commercialization and supply scaling opportunities around recombinant vectors and high-volume manufacturing. In July 2026, Zoetis received European Commission marketing authorization for Poulvac Procerta HVT-ND, a recombinant vector vaccine for Newcastle disease and Marek's disease, expanding the set of licensed options for integrated programs that prioritize fewer hatchery touches and simplified schedules. On the supply side, Huvepharma announced in April 2026 that its Maxton, North Carolina facility expansion increases potential poultry vaccine production capacity to six billion doses annually, supporting tenders and large integrator demand where assured volume, batch release throughput, and consistent cold-chain performance are procurement decision drivers.